Biolojic Design a biotech company specializing in AIdriven antibody innovation announced that Nektar has exercised its license option to develop a program resulting from their collaborative research started in

Amneal Pharmaceuticals Inc has unveiled its Over the Counter Naloxone Hydrochloride Nasal Spray USP mg after securing Abbreviated New Drug Application approval from the US Food and Drug Administration

Junshi Biosciences a leading biopharmaceutical company dedicated to innovative therapies has announced the acceptance of its New Drug Application by the Drug Office of the Hong Kong Special Administrative Region This NDA relates to toripalimab proposed for use in combination

Hanmi Pharmaceutical a leading biopharmaceutical company headquartered in Korea with a focus on oncology obesitymetabolism and rare diseases has recently announced a significant collaboration

GenScript a prominent player in the field of life sciences and biotechnology recently hosted an Open Day event at its facility in Singapore on April th The event attracted more than representatives from Singapore

BeiGene Ltd has received approval from the European Commission for tislelizumabs usage in treating nonsmall cell lung cancer across three distinct indications encompassing both first and secondline

Cullinan Therapeutics Inc a biopharmaceutical company focused on modalityagnostic targeted therapies today announced that clinical data from its Phase trial of CLN in patients with advanced solid tumors

Atom Bioscience a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases has begun enrolling patients

Alkermes plc today announced initiation of the Vibrance study a phase clinical trial evaluating the safety and efficacy of ALKS compared to placebo in patients with narcolepsy type ALKS is the companys novel

Pillar Biosciences Inc the leader in Decision Medicine which develops and distributes nextgeneration sequencing tests to localize testing and reduce time to treatment initiation and testing costs

Astellas Pharma Inc today announced the European Commission has approved a label extension for XTANDITM as monotherapy or in combination with androgen deprivation therapy

Samsung Bioepis Co Ltd today announced that the European Commission has granted marketing authorization for PYZCHIVA a biosimilar to Stelara paving the way for expanding